Detalhe da pesquisa
1.
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
Br J Haematol
; 204(3): 887-891, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38054558
2.
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Am J Hematol
; 98(1): 140-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567778
3.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
4.
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.
Cytotherapy
; 24(8): 767-773, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35597752
5.
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
Am J Hematol
; 97(12): 1580-1588, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36068950
6.
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol
; 97(9): 1170-1177, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731911
7.
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.
Support Care Cancer
; 30(7): 5859-5869, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364733
8.
Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma.
Support Care Cancer
; 30(12): 9771-9779, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36287278
9.
Rap1A, Rap1B, and ß-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.
Yale J Biol Med
; 95(1): 45-56, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35370486
10.
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Cancer
; 127(22): 4233-4239, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374445
11.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
12.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Haematologica
; 106(6): 1599-1607, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499241
13.
Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Cytotherapy
; 23(11): 985-990, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34538575
14.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
15.
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Clin Infect Dis
; 71(9): 2365-2374, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076709
16.
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Biol Blood Marrow Transplant
; 26(12): 2229-2236, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32920204
17.
Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.
Biol Blood Marrow Transplant
; 26(11): 2011-2017, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32717431
18.
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them.
Biol Blood Marrow Transplant
; 26(7): 1288-1297, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135202
19.
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Biol Blood Marrow Transplant
; 26(5): 893-901, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31982543
20.
Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.
Biol Blood Marrow Transplant
; 26(9): 1670-1678, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562858